CARL ANTHONY BLAU, MD
Osteopathic Medicine at Pacific St, Seattle, WA

License number

Washington MD00026522

Personal information

See more information about CARL ANTHONY BLAU at radaris.com

Name

Address

Phone

Carl Blau, age 64

9435 45Th Ave SW, Seattle, WA 98136

(206) 938-0815

Carl A Blau, age 64

5003 119Th Ave SE, Bellevue, WA 98006

(425) 562-2671
(425) 747-7766

Carl A Blau, age 64

601 Mercer Pl, Seattle, WA 98119

Professional information

See more information about CARL ANTHONY BLAU at trustoria.com

Dr. Carl A Blau, Seattle WA - MD (Doctor of Medicine)

Specialties:

Hematology, Medical Oncology, Oncology

Address:

Seattle Cancer Care Alliance
825 Eastlake Ave E, Seattle 98109
(855) 557-0555 (Phone)

Certifications:

Hematology, 1992, Internal Medicine, 1989, Medical Oncology, 1991

Awards:

Healthgrades Honor Roll

Languages:

English, German

Hospitals:

Seattle Cancer Care Alliance
825 Eastlake Ave E, Seattle 98109
University of Washington Medical Center
1959 East Pacific St, Seattle 98195

Education:

Medical School
Ohio State University College Of Medicine and Public Health
Graduated: 1986

Carl Anthony Blau, Seattle WA

Specialties:

Internist

Address:

University Of Washington Medical Ctr, Seattle, WA 98195

Education:

Ohio State University, College of Medicine - Doctor of Medicine

Board certifications:

American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine)

Quantitative/Semi-Quantitative Measurement Of Epor On Cancer Cells

US Patent:

2010029, Nov 25, 2010

Filed:

Oct 8, 2008

Appl. No.:

12/682105

Inventors:

Christopher P. Miller - Seattle WA, US
Carl Anthony Blau - Seattle WA, US
Michael Henke - Freiberg, DE

Assignee:

UNIVERSITY OF WASHINGTON through its Center for Commercialization - Seattle WA

International Classification:

C12Q 1/68, G01N 33/53, G01N 33/574

US Classification:

435 6, 435 792, 435 723

Abstract:

The present invention provides for assays useful in predicting whether a cancer patient risks suffering erythropoietin-induced tumor progression if treated with erythropoietin. More specifically, one embodiment provides for a validated quantitative reverse transcriptase polymerase chain reaction assay that detects erythropoietin receptor expression, thus indicating whether a cancer patient risks suffering erythropoietin-induced tumor progression if treated with erythropoietin.

Methods Of Controlling Cell Differentiation And Growth Using A Fusion Protein And A Drug

US Patent:

7754202, Jul 13, 2010

Filed:

Jan 7, 1999

Appl. No.:

09/582916

Inventors:

Carl Anthony Blau - Seattle WA, US
David M. Spencer - Houston TX, US

Assignee:

Stanford University - Palo Alto CA
University of Washington - Seattle WA

International Classification:

A61K 48/00, C12N 5/00, C12N 15/63

US Classification:

424 9321, 514 44 R, 435325, 4353201, 435455

Abstract:

This invention involves methods and materials for conferring a direct proliferative advantage on a genetically modified subpopulation of cells. Selection is then accomplished by exerting a positive selective stimulus on the engineered cells rather than a negative pressure on nonengineered cells.